Tampilkan postingan dengan label Tom Brokaw. Tampilkan semua postingan
Tampilkan postingan dengan label Tom Brokaw. Tampilkan semua postingan

Rabu, 05 Oktober 2016

Staggering cost of new and effective multiple myeloma care

Staggering cost of new and effective multiple myeloma care


Today’s Managing Health Care Costs Number is $ 162,351


Tom Brokaw had a moving piece in Sunday’s NYT Week in Review about his three years of living with a diagnosis of multiple myeloma.  He’s had back surgery “which reduced my height by 3 inches,” lives with back pain and fatigue, and has developed a new set of colleagues – and a new appreciation for time with his grandchildren.

But this is a blog about health care costs – and this line caught my attention:

Even in remission, cancer alters a patient’s perception of what’s normal. Morning, noon and night, asleep and awake, malignant cells are determined to alter or end your life. Combating cancer is a full-time job that, in my case, requires 24 pills a day, including one that runs $500 a dose.

Here are drugs commonly used to treat multiple myeloma – a disease that had no especially effective treatment until about ten years ago:

Brand Name
Generic
Annual Cost
Velcade
Bortezomib
$  92,352
Thalidomid
Thalidomide
$ 127,346
Revlimid
Lenalidomide
$  162,351
Ninlaro
Ixazomib
$ 124,848
Darzalex
daratumunab
$  54,000
Empliciti
Elotuzamab
$ 105,600
Sources for drug prices Lexicomp via UptoDate, and Medical Letter for Empliciti

This is bad news for patients- Wonkblogrecently reported on the fact that those on Medicare were much more likely to delay Gleevec therapy for chronic myelocytic leukemia if they did not have a subsidy for their medications – no surprise when the median out of pocket spending on this medication was over $8500 per year.

It’s clearly important to shield patients from ruinous out of pocket costs which might make many forgo “high value” therapy.  But a cap on patient out of pocket liability isn’t enough to address the issue.   We need an approach to lower effective drug prices – and simply shifting these from patient to payer will simply raise premiums, and could even decrease pressure on pharmaceutical companies to stop raising prices.